Mirum Pharmaceuticals宣布,其药物Volixibat在针对原发性硬化性胆管炎(PSC)患者开展的Vistas研究中,成功达到了预设的主要疗效终点。该重要里程碑标志着公司在肝胆疾病治疗领域的研发取得关键进展。
Mirum Pharmaceuticals宣布,其药物Volixibat在针对原发性硬化性胆管炎(PSC)患者开展的Vistas研究中,成功达到了预设的主要疗效终点。该重要里程碑标志着公司在肝胆疾病治疗领域的研发取得关键进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.